LifeCycle Pharma Announces Positive Data From LCP-AtorFen Phase I Clinical Program

... LifeCycle Pharma A/S (OMX: LCP) announced today positive results from the company's Phase I clinical program with LCP-AtorFen, a fixed-dose combination product of atorvastatin and fenofibrate for the treatment of high cholesterol levels. The program was a comparative pharmacokinetic study between LCP-AtorFen and Lipitor(R) and Tricor(R) and was carried out in Canada. [click link for full article] ...